NO20075731L - Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon - Google Patents
Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjonInfo
- Publication number
- NO20075731L NO20075731L NO20075731A NO20075731A NO20075731L NO 20075731 L NO20075731 L NO 20075731L NO 20075731 A NO20075731 A NO 20075731A NO 20075731 A NO20075731 A NO 20075731A NO 20075731 L NO20075731 L NO 20075731L
- Authority
- NO
- Norway
- Prior art keywords
- apo
- secretion
- inhibitors
- compounds
- transfer protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67277805P | 2005-04-19 | 2005-04-19 | |
| US75539005P | 2005-12-30 | 2005-12-30 | |
| PCT/US2006/015146 WO2006113910A2 (en) | 2005-04-19 | 2006-04-19 | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075731L true NO20075731L (no) | 2008-01-17 |
Family
ID=37115969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075731A NO20075731L (no) | 2005-04-19 | 2007-11-09 | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8980915B2 (es) |
| EP (1) | EP1877369B1 (es) |
| JP (1) | JP5356017B2 (es) |
| KR (1) | KR20080015792A (es) |
| AU (1) | AU2006236226B2 (es) |
| BR (1) | BRPI0607555A2 (es) |
| CA (1) | CA2605510C (es) |
| CR (1) | CR9528A (es) |
| EA (1) | EA024768B1 (es) |
| EC (1) | ECSP077913A (es) |
| ES (1) | ES2430319T3 (es) |
| GE (1) | GEP20104878B (es) |
| IL (1) | IL186820A0 (es) |
| MX (1) | MX2007013133A (es) |
| NI (1) | NI200700272A (es) |
| NO (1) | NO20075731L (es) |
| NZ (1) | NZ563009A (es) |
| SG (1) | SG164371A1 (es) |
| WO (1) | WO2006113910A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013133A (es) | 2005-04-19 | 2008-03-14 | Surface Logix Inc | Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. |
| ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
| MY162210A (en) | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| WO2008113830A1 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로ＭＩＲｓ |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
| EP2421970B1 (en) | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
| EP3791880A1 (en) | 2009-04-29 | 2021-03-17 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa |
| US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| PE20160158A1 (es) | 2013-06-27 | 2016-03-18 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en pcsk9 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE124408T1 (de) * | 1990-10-16 | 1995-07-15 | Takeda Chemical Industries Ltd | Heterozyklische aminderivate, deren herstellung und deren verwendung. |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5919795A (en) * | 1995-06-07 | 1999-07-06 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| EP1181954A3 (en) * | 1995-06-07 | 2002-08-21 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion |
| CN1209803A (zh) | 1996-01-16 | 1999-03-03 | 布里斯托尔-迈尔斯斯奎布公司 | 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法 |
| BR9714364A (pt) | 1996-11-27 | 2000-03-21 | Pfizer | Amidas inibidoras da secreção de apo b/mtp |
| IL139450A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| US6878707B2 (en) | 2000-01-18 | 2005-04-12 | Novartis Ag | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| CA2468716A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
| JP2003231633A (ja) * | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| AP2006003685A0 (en) * | 2004-02-04 | 2006-08-31 | Pfizer Prod Inc | Substituted quinoline compounds |
| MX2007013133A (es) | 2005-04-19 | 2008-03-14 | Surface Logix Inc | Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. |
-
2006
- 2006-04-19 MX MX2007013133A patent/MX2007013133A/es not_active Application Discontinuation
- 2006-04-19 BR BRPI0607555-0A patent/BRPI0607555A2/pt not_active IP Right Cessation
- 2006-04-19 US US11/407,500 patent/US8980915B2/en active Active
- 2006-04-19 NZ NZ563009A patent/NZ563009A/en not_active IP Right Cessation
- 2006-04-19 EP EP06751011.5A patent/EP1877369B1/en active Active
- 2006-04-19 JP JP2008507927A patent/JP5356017B2/ja active Active
- 2006-04-19 ES ES06751011T patent/ES2430319T3/es active Active
- 2006-04-19 AU AU2006236226A patent/AU2006236226B2/en not_active Ceased
- 2006-04-19 SG SG201005219-9A patent/SG164371A1/en unknown
- 2006-04-19 KR KR1020077026556A patent/KR20080015792A/ko not_active Application Discontinuation
- 2006-04-19 GE GEAP200610378A patent/GEP20104878B/en unknown
- 2006-04-19 CA CA2605510A patent/CA2605510C/en active Active
- 2006-04-19 WO PCT/US2006/015146 patent/WO2006113910A2/en active Application Filing
- 2006-04-19 EA EA200702271A patent/EA024768B1/ru not_active IP Right Cessation
-
2007
- 2007-10-19 NI NI200700272A patent/NI200700272A/es unknown
- 2007-10-21 IL IL186820A patent/IL186820A0/en unknown
- 2007-11-09 NO NO20075731A patent/NO20075731L/no not_active Application Discontinuation
- 2007-11-16 CR CR9528A patent/CR9528A/es not_active Application Discontinuation
- 2007-11-19 EC EC2007007913A patent/ECSP077913A/es unknown
-
2015
- 2015-03-17 US US14/660,453 patent/US9656960B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL186820A0 (en) | 2008-02-09 |
| WO2006113910A2 (en) | 2006-10-26 |
| EP1877369B1 (en) | 2013-07-10 |
| JP5356017B2 (ja) | 2013-12-04 |
| EA200702271A1 (ru) | 2008-04-28 |
| SG164371A1 (en) | 2010-09-29 |
| JP2008538568A (ja) | 2008-10-30 |
| CA2605510A1 (en) | 2006-10-26 |
| KR20080015792A (ko) | 2008-02-20 |
| WO2006113910A3 (en) | 2007-03-22 |
| AU2006236226A1 (en) | 2006-10-26 |
| BRPI0607555A2 (pt) | 2009-09-15 |
| ES2430319T3 (es) | 2013-11-20 |
| CR9528A (es) | 2008-05-21 |
| ECSP077913A (es) | 2008-01-23 |
| CA2605510C (en) | 2013-12-24 |
| EA024768B1 (ru) | 2016-10-31 |
| AU2006236226B2 (en) | 2012-07-05 |
| NZ563009A (en) | 2011-05-27 |
| US20070027183A1 (en) | 2007-02-01 |
| US8980915B2 (en) | 2015-03-17 |
| US9656960B2 (en) | 2017-05-23 |
| NI200700272A (es) | 2008-07-11 |
| EP1877369A4 (en) | 2010-04-14 |
| US20160039765A1 (en) | 2016-02-11 |
| EP1877369A2 (en) | 2008-01-16 |
| GEP20104878B (en) | 2010-01-11 |
| MX2007013133A (es) | 2008-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075731L (no) | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| NO20070506L (no) | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| EA200870380A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета | |
| NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
| NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
| EA200801008A1 (ru) | Гипохолестеринемические соединения | |
| WO2006121861A3 (en) | Biphenylazetidinone cholesterol absorption inhibitors | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| WO2008033562A3 (en) | Kinase inhibitor compounds | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
| WO2010074588A3 (en) | Pharmaceutical compounds | |
| EA201170670A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| EA200802054A1 (ru) | Ингибиторы фермента |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |